Renoprotective effects of berberine as adjuvant therapy for hypertensive patients with type 2 diabetes mellitus: Evaluation via biochemical markers and color Doppler ultrasonography

Dai,Peifeng; Wang,Junhua; Lin,Lin; Zhang,Yanyan; Wang,Zhengping

doi:10.3892/etm.2015.2585

Renoprotective effects of berberine as adjuvant therapy for hypertensive patients with type 2 diabetes mellitus: Evaluation via biochemical markers and color Doppler ultrasonography

Authors:
- Peifeng Dai
- Junhua Wang
- Lin Lin
- Yanyan Zhang
- Zhengping Wang
View Affiliations

Affiliations: Department of Ultrasound, Weifang People's Hospital, Weifang, Shandong 261041, P.R. China, Department of Nephrology, Weifang People's Hospital, Weifang, Shandong 261041, P.R. China, Department of Rheumatology and Immunology, The Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250011, P.R. China
Published online on: June 22, 2015 https://doi.org/10.3892/etm.2015.2585
Pages: 869-876
Copyright: © Dai et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Diabetes and hypertension are complex and serious diseases that may ultimately lead to renal complications. Adequate control of blood glucose and blood pressure contributes to decreased renal risks, but may not be sufficient for certain patients. The current study was undertaken to investigate the renoprotective effects of berberine as an adjuvant therapy to standard hypotensive and hypoglycemic treatment in hypertensive patients with type 2 diabetes mellitus (T2DM). In this 2‑year clinical study, 69 hypertensive patients with T2DM, whose blood pressure and fasting plasma glucose (FPG) were adequately controlled by hypotensive and oral hypoglycemic agents prior to the study, were enrolled and randomly assigned into control (33 cases) and add‑on (36 cases) groups. Berberine was orally administrated to the patients in the add‑on group concomitantly with standard hypotensive and hypoglycemic treatment. Baseline characteristics, including the levels of FPG, glycated hemoglobin, systolic blood pressure, diastolic blood pressure, serum creatinine, urinary albumin‑to‑creatine ratio (UACR), urinary osteopontin and kidney injury molecule‑1 (KIM‑1) were determined. Furthermore, the oxidative stress markers malondialdehyde, urinary 8‑hydroxy‑2'‑deoxyguanosine, superoxide dismutase, glutathione peroxidase and total‑antioxidant capacity, and the inflammatory parameters vascular adhesion molecule‑1, C‑reactive protein and high molecular weight‑adiponectin were evaluated. In addition, ultrasonographic parameters, including peak systolic velocity, end diastolic velocity and renal arterial resistance index were determined. After treatment, it was observed that the control and add‑on treatments were able to adequately control blood pressure and blood glucose. Patients in the add‑on group exhibited significant reductions in renal damage biochemical markers (UACR, urinary osteopontin and KIM‑1) and improved renal hemodynamics, in addition to reduced inflammation and oxidative stress. The present results suggest that berberine is beneficial for hypertensive patients with T2DM as add‑on therapy to standard hypotensive and hypoglycemic agents.

View Figures

View References

1	Wang M, Zhang W, Zhou Y and Zhou X: Association between serum angiotensin-converting enzyme 2 levels and postoperative myocardial infarction following coronary artery bypass grafting. Exp Ther Med. 7:1721–1727. 2014.PubMed/NCBI
2	Chen G, McAlister FA, Walker RL, Hemmelgarn BR and Campbell NR: Cardiovascular outcomes in Framingham participants with diabetes: The importance of blood pressure. Hypertension. 57:891–897. 2011. View Article : Google Scholar : PubMed/NCBI
3	No authors listed. Hypertension in Diabetes study (HDS): II. increased risk of cardiovascular complications in hypertensive type 2 diabetic patients. J Hypertens. 11:319–325. 1993. View Article : Google Scholar : PubMed/NCBI
4	Tamura T, Said S, Harris J, Lu W and Gerdes AM: Reverse remodeling of cardiac myocyte hypertrophy in hypertension and failure by targeting of the renin-angiotensin system. Circulation. 102:253–259. 2000. View Article : Google Scholar : PubMed/NCBI
5	Takatsu M, Hattori T, Murase T, Ohtake M, Kato M, Nashima K, Nakashima C, Takahashi K, Ito H, Niinuma K, Aritomi S, et al: Comparison of the effects of cilnidipine and amlodipine on cardiac remodeling and diastolic dysfunction in Dahl salt-sensitive rats. J Hypertens. 30:1845–1855. 2012. View Article : Google Scholar : PubMed/NCBI
6	Yin M, Westenbrink B, Meissner M, van Gilst WH and de Boer RA: Variable effects of anti-diabetic drugs in animal models of myocardial ischemia and remodeling: A translational perspective for the cardiologist. Int J Cardiol. 169:385–393. 2013. View Article : Google Scholar : PubMed/NCBI
7	Csiszar A, Toth J, Peti-Peterdi J and Ungvari Z: The aging kidney: Role of endothelial oxidative stress and inflammation. Acta Physiol Hung. 94:107–115. 2007. View Article : Google Scholar : PubMed/NCBI
8	Liu L, Liu Y, Qi B, Wu Q, Li Y and Wang Z: Nicorandil attenuates endothelial VCAM-1 expression via thioredoxin production in diabetic rats induced by streptozotocin. Mol Med Rep. 9:2227–2232. 2014.PubMed/NCBI
9	Suzuki H, Sakamoto M, Hayashi T, Iuchi H, Ohashi K, Isaka T, Sakamoto N, Kayama Y, Tojo K, Yoshimura M and Utsunomiya K: Effects of co-administration of candesartan with pioglitazone on inflammatory parameters in hypertensive patients with type 2 diabetes mellitus: A preliminary report. Cardiovasc Diabetol. 12:712013. View Article : Google Scholar : PubMed/NCBI
10	Baradaran A, Nasri H and Rafieian-Kopaei M: Oxidative stress and hypertension: Possibility of hypertension therapy with antioxidants. J Res Med Sci. 19:358–367. 2014.PubMed/NCBI
11	Pan HZ, Zhang L, Guo MY, Sui H, Li H, Wu WH, Qu NQ, Liang MH and Chang D: The oxidative stress status in diabetes mellitus and diabetic nephropathy. Acta Diabetol. 47:(Suppl 1). 71–76. 2010. View Article : Google Scholar : PubMed/NCBI
12	Nakamura A, Shikata K, Nakatou T, Kitamura T, Kajitani N, Ogawa D and Makino H: Combination therapy with an angiotensin-converting-enzyme inhibitor and an angiotensin II receptor antagonist ameliorates microinflammation and oxidative stress in patients with diabetic nephropathy. J Diabetes Investig. 4:195–201. 2013. View Article : Google Scholar : PubMed/NCBI
13	Sato-Horiguchi C, Ogawa D, Wada J, Tachibana H, Kodera R, Eguchi J, Nakatsuka A, Terami N, Shikata K and Makino H: Telmisartan attenuates diabetic nephropathy by suppressing oxidative stress in db/db mice. Nephron Exp Nephrol. 121:e97–e108. 2012. View Article : Google Scholar : PubMed/NCBI
14	Guo Y, Liu Y and Wang Y: Beneficial effect of lycopene on anti-diabetic nephropathy through diminishing inflammatory response and oxidative stress. Food Funct. 6:1150–1156. 2015. View Article : Google Scholar : PubMed/NCBI
15	Ji X, Naito Y, Weng H, Ma X, Endo K, Kito N, Yanagawa N, Yu Y, Li J and Iwai N: Renoprotective mechanisms of pirfenidone in hypertension-induced renal injury: Through anti-fibrotic and anti-oxidative stress pathways. Biomed Res. 34:309–319. 2013. View Article : Google Scholar : PubMed/NCBI
16	Molavi B, Rassouli N, Bagwe S and Rasouli N: A review of thiazolidinediones and metformin in the treatment of type 2 diabetes with focus on cardiovascular complications. Vasc Health Risk Manag. 3:967–973. 2007.PubMed/NCBI
17	Zhou G, Cheung AK, Liu X and Huang Y: Valsartan slows the progression of diabetic nephropathy in db/db mice via a reduction in podocyte injury, and renal oxidative stress and inflammation. Clin Sci (Lond). 126:707–720. 2014. View Article : Google Scholar : PubMed/NCBI
18	Luo Y, Yang SK, Zhou X, Wang M, Tang D, Liu FY, Sun L and Xiao L: Use of Ophiocordyceps sinensis (syn. Cordyceps sinensis) combined with angiotensin-converting enzyme inhibitors (ACEI)/angiotensin receptor blockers (ARB) versus ACEI/ARB alone in the treatment of diabetic kidney disease: A meta-analysis. Ren Fail. 37:614–634. 2015. View Article : Google Scholar : PubMed/NCBI
19	Chandran G, Sirajudeen KN, Yusoff NS, Swamy M and Samarendra MS: Effect of the antihypertensive drug enalapril on oxidative stress markers and antioxidant enzymes in kidney of spontaneously hypertensive rat. Oxid Med Cell Longev. 2014:6085122014. View Article : Google Scholar : PubMed/NCBI
20	Kim J, Shon E, Kim CS and Kim JS: Renal podocyte injury in a rat model of type 2 diabetes is prevented by metformin. Exp Diabetes Res. 2012:2108212012. View Article : Google Scholar : PubMed/NCBI
21	Alhaider AA, Korashy HM, Sayed-Ahmed MM, Mobark M, Kfoury H and Mansour MA: Metformin attenuates streptozotocin-induced diabetic nephropathy in rats through modulation of oxidative stress genes expression. Chem Biol Interact. 192:233–242. 2011. View Article : Google Scholar : PubMed/NCBI
22	Drzewoski J and Zurawska-Klis M: Effect of gliclazide modified release on adiponectin, interleukin-6, and tumor necrosis factor-alpha plasma levels in individuals with type 2 diabetes mellitus. Curr Med Res Opin. 22:1921–1926. 2002. View Article : Google Scholar
23	Zhang SQ, Sun YT, Xu TH, Zhang XF, Liu YZ, Ma MJ, Wang LN and Yao L: Protective effect of metformin on renal injury of C57BL/6J mouse treated with high fat diet. Pharmazie. 69:904–908. 2014.PubMed/NCBI
24	Li MH, Zhang YJ, Yu YH, Yang SH, Iqbal J, Mi QY, Li B, Wang ZM, Mao WX, Xie HG and Chen SL: Berberine improves pressure overload-induced cardiac hypertrophy and dysfunction through enhanced autophagy. Eur J Pharmacol. 728:67–76. 2014. View Article : Google Scholar : PubMed/NCBI
25	Zhao HP, Hong Y, Xie JD, Xie XR, Wang J and Fan JB: Effect of berberine on left ventricular remodeling in renovascular hypertensive rats. Yao Xue Xue Bao. 42:336–341. 2007.(In Chinese). PubMed/NCBI
26	Hong Y, Hui SC, Chan TY and Hou JY: Effect of berberine on regression of pressure-overload induced cardiac hypertrophy in rats. Am J Chin Med. 30:589–599. 2002. View Article : Google Scholar : PubMed/NCBI
27	Cheng F, Wang Y, Li J, Su C, Wu F, Xia WH, Yang Z, Yu BB, Qiu YX and Tao J: Berberine improves endothelial function by reducing endothelial microparticles-mediated oxidative stress in humans. Int J Cardiol. 167:936–942. 2013. View Article : Google Scholar : PubMed/NCBI
28	Li Z, Geng YN, Jiang JD and Kong WJ: Antioxidant and anti-inflammatory activities of berberine in the treatment of diabetes mellitus. Evid Based Complement Alternat Med. 2014:2892642014. View Article : Google Scholar : PubMed/NCBI
29	Chang W, Chen L and Hatch GM: Berberine as a therapy for type 2 diabetes and its complications: From mechanism of action to clinical studies. Biochem Cell Biol. 2014 Dec 1;1–8, [Epub ahead of print]. View Article : Google Scholar : PubMed/NCBI
30	Bhutada P, Mundhada Y, Bansod K, Tawari S, Patil S, Dixit P, Umathe S and Mundhada D: Protection of cholinergic and antioxidant system contributes to the effect ofberberine ameliorating memory dysfunction in rat model of streptozotocin-induced diabetes. Behav Brain Res. 220:30–41. 2011. View Article : Google Scholar : PubMed/NCBI
31	Moghaddam HK, Baluchnejadmojarad T, Roghani M, Khaksari M, Norouzi P, Ahooie M and Mahboobi F: Berberine ameliorates oxidative stress and astrogliosis in the hippocampus of STZ-induced diabetic rats. Mol Neurobiol. 49:820–826. 2014. View Article : Google Scholar : PubMed/NCBI
32	Ni WJ, Ding HH and Tang LQ: Berberine as a promising anti-diabetic nephropathy drug: An analysis of its effects and mechanisms. Eur J Pharmacol. 760:103–112. 2015. View Article : Google Scholar : PubMed/NCBI
33	Alter ML, Kretschmer A, Von Websky K, Tsuprykov O, Reichetzeder C, Simon A, Stasch JP and Hocher B: Early urinary and plasma biomarkers for experimental diabetic nephropathy. Clin Lab. 58:659–671. 2012.PubMed/NCBI
34	Chen Q, He F, Feng X, Luo Z, Zhang J, Zhang L, Wang Y and Tong J: Correlation of Doppler parameters with renal pathology: A study of 992 patients. Exp Ther Med. 7:439–442. 2014.PubMed/NCBI
35	Crutchley TA, Pearce JD, Craven TE, Stafford JM, Edwards MS and Hansen KJ: Clinical utility of the resistive index in atherosclerotic renovascular disease. J Vasc Surg. 49:148–155.e3. 2009. View Article : Google Scholar : PubMed/NCBI
36	Nosadini R, Velussi M, Brocco E, Abaterusso C, Carraro A, Piarulli F, Morgia G, Satta A, Faedda R, Abhyankar A, Luthman H and Tonolo G: Increased renal arterial resistance predicts the course of renal function in type 2 diabetes with microalbuminuria. Diabetes. 55:234–239. 2006. View Article : Google Scholar : PubMed/NCBI
37	Hou YJ, Zhao YY, Xiong B, Cui XS, Kim NH, Xu YX and Sun SC: Mycotoxin-containing diet causes oxidative stress in the mouse. PLoS One. 8:e603742013. View Article : Google Scholar : PubMed/NCBI
38	Zhang M, Feng L, Gu J, Ma L, Qin D, Wu C and Jia X: The attenuation of Moutan Cortex on oxidative stress for renal injury in AGEs-induced mesangial cell dysfunction and streptozotocin-induced diabetic nephropathy rats. Oxid Med Cell Longev. 2014:4638152014. View Article : Google Scholar : PubMed/NCBI
39	Kawai T, Kamide K, Onishi M, Yamamoto-Hanasaki H, Baba Y, Hongyo K, Shimaoka I, Tatara Y, Takeya Y, Ohishi M and Rakugi H: Usefulness of the resistive index in renal Doppler ultrasonography as an indicator of vascular damage in patients with risks of atherosclerosis. Nephrol Dial Transplant. 26:3256–3262. 2011. View Article : Google Scholar : PubMed/NCBI
40	Alderman MH, Cohen H and Madhavan S: Diabetes and cardiovascular events in hypertensive patients. Hypertension. 33:1130–1134. 1999. View Article : Google Scholar : PubMed/NCBI
41	Impellizzeri D, Esposito E, Attley J and Cuzzocrea S: Targeting inflammation: New therapeutic approaches in chronic kidney disease (CKD). Pharmacol Res. 81:91–102. 2014. View Article : Google Scholar : PubMed/NCBI
42	Tripepi G, Mallamaci F and Zoccali C: Inflammation markers, adhesion molecules and all-cause and cardiovascular mortality in patients with ESRD: Searching for the best risk marker by multivariate modeling. J Am Soc Nephrol. 16:(Suppl 1). 83–88. 2005. View Article : Google Scholar
43	Lee HJ, Jeong KH, Kim YG, Moon JY, Lee SH, Ihm CG, Sung JY and Lee TW: Febuxostat ameliorates diabetic renal injury in a streptozotocin-induced diabetic rat model. Am J Nephrol. 40:56–63. 2014. View Article : Google Scholar : PubMed/NCBI
44	Bae EH, Kim IJ, Joo SY, Kim EY, Choi JS, Kim CS, Ma SK, Lee J and Kim SW: Renoprotective effects of the direct renin inhibitor aliskiren on gentamicin-induced nephrotoxicity in rats. J Renin Angiotensin Aldosterone Syst. 15:348–361. 2014. View Article : Google Scholar : PubMed/NCBI
45	Šilhavý J, Zídek V, Landa V, Šimáková M, Mlejnek P, Oliyarnyk O, Malínská H, Kazdová L, Mancini M and Pravenec M: Rosuvastatin ameliorates inflammation, renal fat accumulation, and kidney injury in transgenic spontaneously hypertensive rats expressing human C-reactive protein. Physiol Res. 64:295–301. 2015.PubMed/NCBI
46	Park JW, Bae EH, Kim IJ, Ma SK, Choi C, Lee J and Kim SW: Renoprotective effects of paricalcitol on gentamicin-induced kidney injury in rats. Am J Physiol Renal Physiol. 298:F301–F313. 2010. View Article : Google Scholar : PubMed/NCBI
47	Shibata R, Sato K, Pimentel DR, Takemura Y, Kihara S, Ohashi K, Funahashi T, Ouchi N and Walsh K: Adiponectin protects against myocardial ischemia reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat Med. 11:1096–1103. 2005. View Article : Google Scholar : PubMed/NCBI
48	Oliveira CS, Saddi-Rosa P, Crispim F, Canani LH, Gerchman F, Giuffrida FM, Vieira JG, Velho G and Reis AF: Association of ADIPOQ variants, total and high molecular weight adiponectin levels with coronary artery disease in diabetic and non-diabetic Brazilian subjects. J Diabetes Complications. 26:94–98. 2012. View Article : Google Scholar : PubMed/NCBI
49	Kopf S, Oikonomou D, von Eynatten M, Kieser M, Zdunek D, Hess G, Morcos M, Forsblom C, Bierhaus A, Groop PH, Nawroth PP and Humpert PM: Urinary excretion of high molecular weight adiponectin is an independent predictor of decline of renal function in type 2 diabetes. Acta Diabetol. 51:479–489. 2014.PubMed/NCBI
50	Wu YH, Chuang SY, Hong WC, Lai YJ, Chang GJ and Pang JH: Berberine reduces leukocyte adhesion to LPS-stimulated endothelial cells and VCAM-1 expression both in vivo and in vitro. Int J Immunopathol Pharmacol. 25:741–750. 2012.PubMed/NCBI
51	Choo BK and Roh SS: Berberine protects against esophageal mucosal damage in reflux esophagitis by suppressing proinflammatory cytokines. Exp Ther Med. 6:663–670. 2013.PubMed/NCBI
52	Liu WH, Hei ZQ, Nie H, Tang FT, Huang HQ, Li XJ, Deng YH, Chen SR, Guo FF, Huang WG, Chen FY and Liu PQ: Berberine ameliorates renal injury in streptozotocin-induced diabetic rats by suppression of both oxidative stress and aldose reductase. Chin Med J (Engl). 121:706–712. 2008.PubMed/NCBI
53	Wu D, Wen W, Qi CL, Zhao RX, Lü JH, Zhong CY and Chen YY: Ameliorative effect of berberine on renal damage in rats with diabetes induced by high-fat diet and streptozotocin. Phytomedicine. 19:712–718. 2012. View Article : Google Scholar : PubMed/NCBI